Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large XXXX : a meta-analysis.

@entity1 @entity3726 @entity1892
The aim of this study is to systematically evaluate the safety and efficacy of rituximab plus @entity3726 (R- @entity3726 combined regimen) in @entity1 with previously untreated @entity1892 ( @entity1892 ). Electronic database were searched for randomized-controlled studies only comparing R- @entity3726 to @entity3726 standard alone in @entity1 with untreated @entity1892 were included. The risk ratios (RRs) with their 95% corresponding intervals (95% CI) were employed to estimate the efficacy of overall response (OR), complete response (CR), risk of dying and relapse rate in followed-up period. Total ten case-control studies containing 2941 @entity1 met the inclusion criteria. The addition of R to standard @entity3726 were showed to increase the proportion of CR (RR=1.23, 95% CI=1.13-1.35, P<0.00001) and OR (RR=1.39, 95% CI=1.24-1.55, P<0.00001) in a fixed-effect model, indicating that rituximab combined with @entity3726 regimen is efficacy than @entity3726 alone. It did not increase the overall risk of dying as a consequence of infection (RR=0.79, 95% CI=0.55-1.13, P=0.20). Furthermore, the relapse rates is significantly lower in R- @entity3726 (RR=0.52, 95% CI=0.38-0.71, P<0.0001). The adverse effects were also not significant (P>0.05). In summary, R- @entity3726 regimen is superior to standard @entity3726 in terms of overall response and complete response. It does not increase the incidence of adverse effects. However, more studies concerning different age groups and special @entity1 are needed to discuss the potential role of R in @entity1892 .
